Pirtobrutinib is a secondary carboxamide formed by the condensation of the carboxy group of 5-fluoro-2-methoxybenzoic acid with the amino group of 5-amino-3-[4-(aminomethyl)phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]-1H-pyrazole-4-carboxamide. It is a BTK inhibitor used to treat adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. It functions as an EC 2.7.10.2 inhibitor, an antineoplastic agent, and an apoptosis inducer. It belongs to the classes of monomethoxybenzenes, monofluorobenzenes, benzamides, secondary carboxamides, primary carboxamides, organofluorine compounds, pyrazoles, and primary amino compounds.
Health Hazard
Environmental Hazard